Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

Affiliations

• 1 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. kris.white@mssm.edu nevan.krogan@ucsf.edu adolfo.garcia-sastre@mssm.edu.
• 2 Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• 4 Department of Microbiology and Immunology and Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, MD, USA.
• 5 Quantitative Biosciences Institute (QBI), University of California, San Francisco, CA 94158, USA.
• 6 J. David Gladstone Institutes, San Francisco, CA 94158, USA.
• 7 QBI Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
• 8 Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
• 9 Huffington Foundation Center for Cell-Based Research in Parkinson's Disease, Department of Cell, Developmental, and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• 10 Research and Development Department, PharmaMar, 28770 Colmenar Viejo, Madrid, Spain.
• 11 Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 75724 Paris Cedex 15, France.
• 12 Howard Hughes Medical Institute, University of California, San Francisco, CA 94143, USA.
• 13 Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• 14 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• # Contributed equally.